Published in Medical Patent Week, January 7th, 2007
Tikvah Therapeutics is led by President and CEO Harold H. Shlevin, PhD, and will focus on the psychiatry and neurology markets.
Tikvah Therapeutics will explore new uses for already approved compounds in which the new therapeutic uses have been confirmed in multiple, new clinical proof-of-concept studies. This strategy shortens product development timelines -- in some cases by up to seven years -- and substantially...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.